IMFINZI APPROVED IN CANADA AS FIRST AND ONLY PERIOPERATIVE IMMUNOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
ASTRAZENECA CANADA: HEALTH CANADA GRANTED NOTICE OF COMPLIANCE FOR IMFINZI (DURVALUMAB) FOR MIBC
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.